US Patent

US10960009 — Methods of treating schizophrenia and depression

Method of Use · Assigned to Intra Cellular Therapies Inc · Expires 2034-12-03 · 9y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of certain compounds for treating residual symptoms of psychosis or schizophrenia, including long-acting injectable formulations.

USPTO Abstract

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-814 — lumateperone-tosylate

Patent Metadata

Patent number
US10960009
Jurisdiction
US
Classification
Method of Use
Expires
2034-12-03
Drug substance claim
No
Drug product claim
No
Assignee
Intra Cellular Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.